Trials / Completed
CompletedNCT00186394
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (estimated)
- Sponsor
- Stanford University · Academic / Other
- Sex
- All
- Age
- 18 Years – 61 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of NHL.
Detailed description
To determine safety and toxicity of a regimen of high dose chemotherapy with allogeneic peripheral blood progenitor cell transplantation; determine the efficacy of the procedure by following clinical outcomes and quality of life measures; and evaluate graft versus host disease incidence and severity with regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | ablative allogeneic hematopoietic cell transplantation |
Timeline
- Start date
- 2000-04-01
- Primary completion
- 2006-12-01
- Completion
- 2006-12-01
- First posted
- 2005-09-16
- Last updated
- 2010-07-27
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00186394. Inclusion in this directory is not an endorsement.